+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Respiratory syncytial virus (RSV) is a disease that has proved challenging for drugmakers for decades. RSV affects newborns and older adults in particular. Recently, several pharmaceutical companies have reported strong results in the development of RSV vaccines. This is a significant development as RSV has never had a vaccine before and cases have been on the rise.
Moderna announced on Tuesday that its final phase RSV vaccine is 84% effective in preventing lower respiratory tract disease in adults over 60, and 83% effective at preventing severe disease. The company intends to file for Food and Drug Administration (FDA) approval soon. Pfizer and GSK have both already submitted data to the FDA on RSV vaccines for older adults and a decision is expected in May 2023. GSK's vaccine is reported to be 83% effective overall and more than 94% protective against severe RSV in adults over 60 with underlying health issues. However, it also appears to have more side effects compared to Pfizer's vaccine, which was found to be 67% effective overall and 86% protective against severe disease. Pfizer is also developing a maternal RSV vaccine, designed to transfer antibodies from mother to unborn child, which has been reported to be 82% effective in protecting infants for their first 90 days of life. Johnson & Johnson and Bavarian Nordic are also working on the development of RSV vaccines.
Research and Markets offers more information on this topic:
